CAS: 3751-48-2; 3-(3-Methylphenyl)Propionic Acid

上下游产品

CAS号313058-61-6 2-(3-methylphen... | CAS号3029-79-6 3-甲基肉桂酸 | CAS号620-23-5 间甲基苯甲醛 | CAS号620-13-3 3-甲基苄溴 | CAS号141-82-2 丙二酸 | CAS号6432-79-7 [(3-methylpheny... | CAS号620-19-9 间甲基氯化苄 | CAS号105-53-3 丙二酸二乙酯 | CAS号4593-38-8 5-甲基-1-茚酮 | CAS号39627-61-7 7-甲基-1-茚酮 | CAS号29417-96-7 3-(3-甲基-苯基)丙酸甲酯 | CAS号898768-36-0 CYCLOPENTYL 2-(... | CAS号92-47-7 2H-1-Benzopyran... | CAS号140840-98-8 8-methyl-3,4-di...

📜3-甲基苄溴置于氢氧化钾,硫酸,Sodium Hydride体系中,用 乙二醇二甲醚 用作溶剂,化学反应 42.5H,反应生成3-(3-甲基苯基)丙酸
参考文献:茚满亚胺.1.设计和合成(e)-2-(4,6-二氟-1-茚二亚基)乙酰胺,这是一种具有消炎和镇痛作用的强效中枢肌肉松弛剂.
标题:茚满亚胺.1.设计和合成(e)-2-(4,6-二氟-1-茚二亚基)乙酰胺,这是一种具有消炎和镇痛作用的强效中枢肌肉松弛剂.
摘要:衍生自肉桂酰胺1,(e)-N-环丙基-3-(3-氟苯基)丙-2-烯酰胺和β-甲基肉桂酰胺2,(e)-N-环丙基-3-(3)的刚性环状类似物的设计-氟苯基)丁-2-烯酰胺已导致发现有效的中枢性肌肉松弛剂(e)-2-(4,6-二氟-1-茚二亚基)乙酰胺17.化合物17还具有有效的抗炎和抗炎作用.镇痛作用.本文描述了17和67类似物的合成及其肌肉松弛,抗炎和止痛结构-活性的关系.化合物17已进入i期临床试验.
Doi:10.1021/jm020067S

专利信息

专利号:US-12304894-B2
优先权日:2019-04-17
标题 :Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1)
发明人：FARDELLA BELLO CARLOS ENRIQUE; LAGOS ARÉVALO CARLOS FERNANDO; VECCHIOLA CÃ?RDENAS ANDREA PAOLA; ALLENDE SANZANA FIDEL ALEJANDRO; DIETHELM VARELA BENJAMIN MANUEL; RECABARREN GAJARDO GONZALO IVAN; GONZÃ?LEZ CISTERNA PABLO MARCELO
权利人:UNIV PONTIFICIA CATOLICA CHILE
摘要:The present invention relates to compounds derived from adamantyl oxadiazoles and the pharmaceutically acceptable solvates, hydrates and salts of same. These compounds are suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1), as well as in the production of a drug for treating conditions and diseases such as high blood pressure, obesity, dyslipidaemia, type 2 diabetes, insulin resistance, glaucoma, metabolic syndrome, cognitive disorders, osteoporosis, immune disorders, depression and other conditions. Also provided is a pharmaceutical composition comprising the compounds and a method for preparing said composition.

专利号:CN-112679336-A
优先权日:2020-12-29
标 题 :A kind of method of heterogeneous palladium metal catalyzed synthesis of phenylpropionic acid compounds

专利号:WO-2020210922-A1
优先权日:2019-04-17
标题 :Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-hsd1)

专利号:CA-3136838-A1
优先权日:2019-04-17
标 题:Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11.beta.-hsd1)

专利号:US-2022194909-A1
优先权日:2019-04-17
标 题 :Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11b-hsd1)

专利号:WO-2014016766-A1
优先权日:2012-07-25
标 题:Guanidine derivatives as trpc modulators
发明人：LINGAM V S PRASADA RAO; THOMAS ABRAHAM; DAHALE DNYANESHWAR HARISHCHANDRA; RATHI VIJAY EKNATH; KHAIRATKAR-JOSHI NEELIMA; MUKHOPADHYAY INDRANIL
权利人:GLENMARK PHARMACEUTICALS SA
摘要:The present invention is directed to guanidine derivatives as inhibitors of transient receptor potential canonical channels (TRPC channels), in particular TRPC3 and/or TRPC6 and/or TRPC7 activity, more particularly TRPC6 activity. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by TRPC channels (Formula (I)).